Evaluating the effectiveness of the NHS Health Check programme in South England: a quasi-randomised controlled trial.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 09 2019
Historique:
entrez: 23 9 2019
pubmed: 23 9 2019
medline: 2 10 2020
Statut: epublish

Résumé

To evaluate uptake, risk factor detection and management from the National Health Service (NHS) Health Check (HC). This is a quasi-randomised controlled trial where participants were allocated to five cohorts based on birth year. Four cohorts were invited for an NHS HC between April 2011 and March 2015. 151 general practices in Hampshire, England, UK. 366 005 participants born 1 April 1940-31 March 1976 eligible for an NHS HC. NHS HC invitation. HC attendance and absolute percentage changes and ORs of (1) detecting cardiovascular disease (CVD) 10-year risk >10% and >20%, smokers, and total cholesterol (TC) >5.5 mmol/L and >7.5 mmol/L; (2) diagnosing hypertension, type 2 diabetes mellitus, chronic kidney disease (CKD) and atrial fibrillation (AF); and (3) new interventions with statins, antihypertensives, antiglycaemics and nicotine replacement therapy (NRT). HC attendance rose from 12% to 30% between 2011/2012 and 2014/2015 (p<0.001). HC invitation increased detection of CVD risk >10% (2.0%-3.6, p<0.001) and >20% (0.1%-0.6%, p<0.001-0.392), TC >5.5 mmol/L (4.1%-7.0%, p<0.001) and >7.5 mmol/L (0.3%-0.4% p<0.001), hypertension (0.3%-0.6%, p<0.001-0.003), and interventions with statins (0.2%-0.9%, p<0.001-0.017) and antihypertensives (0.1%-0.6%, p<0.001-0.205). There were no consistent differences in detection of smokers, NRT, or diabetes, AF or CKD. Multivariate analyses showed associations between HC invitation and detecting CVD risk >10% (OR 8.01, 95% CI 7.34 to 8.73) and >20% (5.86, 4.83 to 7.10), TC >5.5 mmol/L (3.72, 3.57 to 3.89) and >7.5 mmol/L (2.89, 2.46 to 3.38), and diagnoses of hypertension (1.33, 1.20 to 1.47) and diabetes (1.34, 1.12 to 1.61). OR of CVD risk >10% plus statin and >20% plus statin, respectively, was 2.90 (2.36 to 3.57) and 2.60 (1.92 to 3.52), and for hypertension plus antihypertensive was 1.33 (1.18 to 1.50). There were no associations with AF, CKD, antiglycaemics or NRT. Detection of several risk factors varied inversely by deprivation. HC invitation increased detection of cardiovascular risk factors, but corresponding increases in evidence-based interventions were modest.

Identifiants

pubmed: 31542745
pii: bmjopen-2019-029420
doi: 10.1136/bmjopen-2019-029420
pmc: PMC6756325
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e029420

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Prev Med. 2015 Sep;78:1-8
pubmed: 26051202
Heart. 2015 Aug;101(15):1182-9
pubmed: 26041770
J Public Health (Oxf). 2016 Sep;38(3):552-559
pubmed: 26350481
J Public Health (Oxf). 2011 Sep;33(3):422-9
pubmed: 21546385
BMJ Open. 2015 Apr 13;5(4):e007578
pubmed: 25869692
J Public Health (Oxf). 2018 Jun 1;40(2):e151-e156
pubmed: 28633511
BMC Health Serv Res. 2017 Jun 14;17(1):405
pubmed: 28615019
J Public Health (Oxf). 2013 Mar;35(1):85-91
pubmed: 22829660
PLoS Med. 2018 Mar 6;15(3):e1002517
pubmed: 29509767
J Public Health (Oxf). 2015 Jun;37(2):187-92
pubmed: 26022810
Br J Gen Pract. 2018 Jul;68(672):e449-e459
pubmed: 29914882
BMJ Open. 2016 Jan 13;6(1):e008840
pubmed: 26762161
BMJ Open. 2017 Aug 11;7(8):e017169
pubmed: 28801437
J Public Health (Oxf). 2016 Sep;38(3):543-551
pubmed: 26408822
J Public Health (Oxf). 2013 Mar;35(1):92-8
pubmed: 23104892
BMC Fam Pract. 2015 Mar 08;16:33
pubmed: 25879731
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816
pubmed: 23440795
N Engl J Med. 2011 Sep 29;365(13):e27
pubmed: 21913835
BMJ. 2013 Sep 04;347:f5227
pubmed: 24004991
Prev Med. 2013 Aug;57(2):129-34
pubmed: 23701848
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Lancet. 2016 Nov 19;388(10059):2532-2561
pubmed: 27616593
BMC Fam Pract. 2016 Mar 24;17:35
pubmed: 27009045
BMC Public Health. 2012 Nov 01;12:944
pubmed: 23116213
Cochrane Database Syst Rev. 2012 Oct 17;10:CD009009
pubmed: 23076952
J Public Health (Oxf). 2015 Jun;37(2):193-4
pubmed: 26022811
Can J Cardiol. 2009 Aug;25(8):451-2
pubmed: 19668778
BMJ Open. 2013 Mar 05;3(3):
pubmed: 23468469

Auteurs

Oliver Kennedy (O)

Faculty of Medicine, University of Southampton, Southampton, UK ok4g13@soton.ac.uk.

Fangzhong Su (F)

Faculty of Medicine, University of Southampton, Southampton, UK.

Robert Pears (R)

Public Health Directorate, Hampshire County Council, Hampshire, UK.

Emily Walmsley (E)

Faculty of Medicine, University of Southampton, Southampton, UK.

Paul Roderick (P)

Faculty of Medicine, University of Southampton, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH